US2022008437A1PendingUtilityA1

Use of prostaglandin E1 methyl ester in manufacture of vasodilator

37
Assignee: XIAN LIBANG ZHAOXIN BIOTECHNOLOGY CO LTDPriority: Nov 27, 2018Filed: Oct 28, 2019Published: Jan 13, 2022
Est. expiryNov 27, 2038(~12.3 yrs left)· nominal 20-yr term from priority
Inventors:Rutao WangLong AnYi ZhaoJinghua PangTao Chen
A61P 7/02A61P 9/00A61P 3/10A61P 9/08A61K 31/5575A61P 9/04A61P 17/00A61P 17/10A61P 9/10A61P 17/02
37
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The disclosure provides use of prostaglandin E1 methyl ester in the manufacture of a vasodilator. The prostaglandin E1 methyl ester has a structure represented by formula (I). the vasodilator is a drug for the treatment of microcirculation disorder, coronary heart disease, angina pectoris, heart failure, pulmonary heart disease, cerebral infarction, amniotic fluid embolism, or scleroderma.

Claims

exact text as granted — not AI-modified
1 . A method for dilating blood vessels comprising: administering to a subject prostaglandin E1 methyl ester, wherein the prostaglandin E1 methyl ester has a structure represented by formula (I) 
       
         
           
           
               
               
           
         
       
     
     
         2 . The method according to  claim 1 , wherein the method is a method for the treatment of microcirculation disorder, coronary heart disease, angina pectoris, heart failure, pulmonary heart disease, cerebral infarction, amniotic fluid embolism, or scleroderma. 
     
     
         3 . The method according to  claim 2 , wherein the method is a method for dilating blood vessels to achieve the treatment of microcirculation disorder, coronary heart disease, angina pectoris, heart failure, pulmonary heart disease, cerebral infarction, amniotic fluid embolism, or scleroderma. 
     
     
         4 . The method according to  claim 2 , wherein the microcirculation disorder is caused by thromboangiitis obliterans, arteriosclerosis obliterans, diabetes, frostbites, burns or bedsores. 
     
     
         5 . The method according to  claim 2 , wherein the method is a method for the treatment of scleroderma and for improving the skin thickness and/or collagen deposition of an animal with scleroderma to achieve the treatment of scleroderma. 
     
     
         6 . The method according to  claim 5 , wherein the animal is a mammal. 
     
     
         7 . The method according to  claim 5 , wherein the animal is a human.

Join the waitlist — get patent alerts

Track US2022008437A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.